Biospecifics Technologies Corp.   Report issue

Contributed to NME For profit Phase 1 Phase 3
Founded: Lynbrook NY United States (1957)
Status: Acquired by Endo Pharmaceuticals (2020) → now Bristol-Myers Squibb (2001)

Organization Overview

First Clinical Trial
2003
NCT00260429
First Marketed Drug
1965
collagenase clostridium histolyticum (xiaflex)
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Advance Biofactures | ADVANCE BIOFACTURES | Advance Biofactures Corporation

Active Ingredients

Marketed Drugs (1)

collagenase clostridium histolyticum (xiaflex) (1965)

Drugs in Phase 3 Trials (1)

collagenase clostridium histolyticum (xiaflex) (5 trials)

Drugs in Phase 1 Trials (1)

sodium chloride (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Bursitis (Phase 2)

Dupuytren Contracture (Phase 3)

Leiomyoma (Phase 1)

Lipoma (Phase 2)

Myofibroma (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 2